Long

CRXT Clarus Therapeutics Bullish Reversal

252
CRXT Clarus Therapeutics had 3 green days after its sell-off to all time low.
This should signal a reversal pattern.
Clarus Therapeutics has the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions called JATENZO.

The fist target is the $1.1 private placement offering price and then the $2.10 resistance.
Few months ago they had another private placement at $4.96 per unit, so we can take that into consideration as well.
Needham & Company LLC has a Price Target of $8 for CRXT (that is the ultimate goal).

I think it can easily double from here.

Looking forward to read your opinion about it.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.